Floatz logo

4,5,6,7-TETRACHLORO-2',4',5',7'-TETRAIODOFLUORESCEIN DISODIUM SALT

Cancer Metastatic to the Liver

Provectus Biopharmaceuticals, Inc.Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

171 Active assets in the Cancer Metastatic to the Liver cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

4,5,6,7-TETRACHLORO-2',4',5',7'-TETRAIODOFLUORESCEIN DISODIUM SALT is also rated in:

cutaneous melanomaDormant
B
Indicative ·
57 / 100
View asset →
melanomaDormant
CCC
Indicative ·
55 / 100
View asset →
uveal melanomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →